TY - JOUR
T1 - Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
AU - Badalamenti, Giuseppe
AU - Ortega, Cinzia
AU - Calipari, null
AU - Giannicola, null
AU - Venditti, null
AU - Latiano, null
AU - Badalamenti, Giuseppe
AU - Petrelli, null
AU - Masini, null
AU - Ottaviani, Davide
AU - Ottone, null
AU - Salvatore, null
AU - Aglietta, null
AU - Cascinu, Stefano
AU - Mazzara, Calogero
AU - Catalano, Vincenzo
AU - Bertolini, null
AU - Badalamenti, null
AU - Fratto, null
AU - Tampellini, null
AU - Caroti, Cinzia
AU - Addeo, Raffaele
AU - Maiello, Evaristo
AU - Vincenzi, Bruno
AU - Giordani, null
AU - Silvestris, Nicola
AU - Falcone, Alfredo
AU - Ibrahim, Toni
AU - Tonini, Giuseppe
AU - Berardi, Rossana
AU - Barni, Sandro
AU - Santini, Daniele
AU - Fabbri, null
AU - Virzi, Vladimir
PY - 2012
Y1 - 2012
N2 - Background: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this studywas to survey the natural history of bone metastasis in CRC.Patients and methods: This retrospective, multicenter, observational study of 264 patients with CRC involving boneexamined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency,zoledronic acid therapy, and disease outcomes.Results: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the mostcommon site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time fromCRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiationand pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs.Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival.Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid.Conclusion: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid inthis setting.
AB - Background: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this studywas to survey the natural history of bone metastasis in CRC.Patients and methods: This retrospective, multicenter, observational study of 264 patients with CRC involving boneexamined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency,zoledronic acid therapy, and disease outcomes.Results: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the mostcommon site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time fromCRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiationand pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs.Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival.Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid.Conclusion: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid inthis setting.
UR - http://hdl.handle.net/10447/75251
M3 - Article
SN - 0923-7534
VL - 23
SP - 2072
EP - 2077
JO - Annals of Oncology
JF - Annals of Oncology
ER -